|
Age
|
–
|
–
|
> 0.05
|
|
Gender male: female
|
1.2:0.8
|
1.3:0.7
|
> 0.05
|
|
Clinical risk factors
|
|
Diabetes
|
26 (23.6%)
|
19 (25%)
|
> 0.05
|
|
Liver failure
|
12 (11%)
|
19 (25%)
|
> 0.05
|
|
Chronic lung diseases
|
15 (13.6%)
|
16 (21%)
|
> 0.05
|
|
Renal failure
|
12 (35.2%)
|
18 (24.3%)
|
> 0.05
|
|
Solid organ malignancy
|
7 (20.6%)
|
12 (16.2%)
|
> 0.05
|
|
Hematological malignancies
|
6 (17.6%)
|
16 (21%)
|
> 0.05
|
|
Exposure of broad spectrum antibiotics
|
28 (82.3%)
|
56 (73.7%)
|
> 0.05
|
|
Exposure of anti-fungal
|
3 (8.8%)
|
38 (50%)
|
2.2 (1.9–3.2); 0.03
|
|
Under gone abdominal surgeries
|
7 (20.6%)
|
19 (25%)
|
> 0.05
|
|
On immune suppressive medications
|
6 (17.6%)
|
38 (50%)
|
2.4 (2.1–2.9); 0.04
|
|
On hemodialysis
|
12 (35.2%)
|
22 (29.7%)
|
> 0.05
|
|
Prolonged intensive care stay ≥14 days
|
8 (23.5%)
|
56 (73.7%)
|
3.3 (2.2–4.5); 0.03
|
|
On central venous line > 8 days
|
16 (47.0%)
|
64 (84.2%)
|
4.3 (3.4–5.4); 0.03
|
|
On urinary catheters > 10 days
|
18 (52.9%)
|
38 (50%)
|
> 0.05
|
|
Mechanical ventilation
|
|
Presence of prosthesis or implant
|
12 (35.5%)
|
26 (35.5%0
|
> 0.05
|
|
Total parenteral nutrition
|
6 (17.6%)
|
16 (21%)
|
> 0.05
|
|
Candiduria
|
6 (17.6%)
|
16 (21%)
|
> 0.05
|
|
6 (17.6%)
|
12 (15.7%)
|
> 0.05
|
|
Duration of treatment
|
16.8 ± 2.2 days
|
26.8 ± 2.2 days
|
0.03
|
|
Out come
|
|
Complete recovery
|
28 (82.3%)
|
48 (63.1%)
|
0.04
|
|
Death
|
6 (17.7%)
|
28 (36.9%)
|
0.04
|
|
Day 7
|
2 (33.3%)
|
18 (64.2%)
|
0.03
|
|
Day 30
|
4 (66.6%)
|
10 (35.8%)
|
0.04
|
